Skip to main content


SWF International Research Network

For Professionals

SWF International Research Network

The mission of the SWFIRN is to provide a forum within the domestic and international medical and research community to foster collaborative research, and consensus guidelines, and develop improved treatment models while facilitating clinical studies. 

SWFIRN Steering Committee

Dr. Matthew Shirley, Ph.D
Dr. Doug Marchuk, Ph.D
Dr. Kristen Kelley, MD
Dr. Akira Yoshi, MD
Dr. Steve E. Roach, MD

SWFIRN Attendees at 2016 SWFIRN Inaugural Meeting

Dr. Jack Arbiser, MD, Dermatology
Dr. Sanjoy Bhattacharya, PhD, Resident
Dr. Craig Burkhart, MD, Dermatology
Dr. Sarah Champlin, MD, Neurology
Dr. Harry Chugani, MD, Neurology
Dr. Larry Eichenfeld, MD, Dermatology
Dr. Heather Etchevers, Ph.D., Paris, France
Dr. Llona Frieden, MD, Neurology
Dr. Anne Fulton, MD, Opthalmology
Dr. Roy Geronemus, MD, Dermatology
Dr. Adrienne Hammill, MD, ONC
Dr. Michael Lawton, MD, Neurology
Dr.Jeff Loeb, MD, Ph.D., Neurology
Dr. Doug Marchuk, Ph.D., Genetics
Dr. Dan Miles, MD, Neurology
Dr. Stuart Nelson, MD, Dermatology
Dr. Paula North, MD, Ph.D., Pathology
Dr. Jonathan Pevsner,MD, Ph.D
Dr. Anna Pinto, MD, Ph.D., Neurology
Dr. Raul Rodriquez, MD, Neurology, San Juan, PR
Dr. Mustafa Sahin, MD, Ph.D., Neurology
Dr. Meghan Tollefson, Ph.D., Dermatology
Dr. Angus Wilfong, MD, Neurology

Back Row: Thurein Htoo; Francesca Galeffi, MD; Jan Pruszak, MD; Aliece Goodman, Ph.D.; Michael Fautsch, Ph.D.; Sana Nasim, Ph.D.; Csaba Juhasz, MD, Ph.D.; Michael Onken, Ph.D.; and Jeff Loeb, MD, Ph.D.
Seated Front Row: Doug Marchuk, Ph.D.; Anna Pinto, MD, Ph.D.; Joyce Biscoff, Ph.D.; and Matt Shirley, Ph.D.
Not Pictured: Lisa Arkin, MD; Beth Drolet, MD; and Naiem Issa, Ph.D.

  • Courtney Shirley Ph.D., SWF Science Director
    Courtney Shirley Ph.D., SWF Science Director

    "Animal models are not only critical for studying disease mechanisms and potential treatments, but they also play a crucial role in drug development. Before a new drug can be tested in humans, it must go through rigorous testing in animal models to ensure its safety and efficacy. Animal models can provide valuable insights into potential side effects, optimal dosing, and drug interactions, speeding up the drug development process and bringing new treatments to patients faster."